Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02768337
Other study ID # CamBMT1
Secondary ID 2013-002398-2312
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date March 10, 2015
Est. completion date August 12, 2021

Study information

Verified date January 2024
Source Cambridge University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.


Description:

Brain metastases occur in 20-40% of all patients with cancer, with an incidence 10 times higher than that of primary malignant brain tumours. patients with brain metastases are an underserved population. Overall they have a poor prognosis with a median survival of 1-2 months with corticosteroids and only 5-7 months after whole brain radiotherapy. An important factor in the poor prognosis of patients with brain metastases is the inability of many drugs to penetrate the blood-brain-barrier into tumour tissue.Combination therapy with surgical excision, radiotherapy and novel drugs could potentially improve the prognosis for some patients. CamBMT1 is an open label, 3 Arm randomised Phase 2 trial investigating whether administration of a low dose of targeted radiotherapy during afatinib treatment could increase the concentration of drug penetration into brain metastases. Eligible patients in Phase 2 will be randomised to 1 of 3 Arms: Arm 1: no radiotherapy Arm 2: 2Gy radiotherapy Arm 3: 4Gy radiotherapy All patients will also receive 11 days of afatinib treatment at the recommended Phase 2 dose, previously determined in a Phase 1b safety run-in phase. On Day 10, of afatinib treatment patients randomised to Arms 2 or 3 will receive their allocated dose of radiotherapy On Day 12, patients will undergo neurosurgical resection of their brain metastasis/ses. Patients will be followed up on Day 22-28 and on Day 41 +/- 7 days For the primary outcome measure, samples for measurement of plasma concentration of afatinib will be taken pre-treatment, on day 10 and Day 12 post-resection. Tumour tissue from the resected brain metastasis will be taken on day 12 for measurement of afatinib concentration. The primary outcome measure is the ratio of these concentrations. The patient population studied will be breast/likely breast or lung/likely lung primary cancers with operable brain metastases.


Recruitment information / eligibility

Status Terminated
Enrollment 26
Est. completion date August 12, 2021
Est. primary completion date August 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Operable brain metastases from likely breast or lung origin as determined by local MDT. Both of the following groups of patients may be considered eligible: 1. Patients with a past history of histologically/cytologically confirmed breast or lung cancer, now presenting with a new likely brain metastasis from that primary. 2. Patients presenting with new, primary (breast/lung) tumours, plus synchronous, operable brain metastases, without pre-op tissue diagnosis. - ECOG performance score 0, 1 or 2. - Aged 18 years or older. - Written informed consent. - Patients are allowed to take oral corticosteroids however the plan should be for them to receive a stable dose of corticosteroids for at least 3 days before neurosurgery (i.e. trial days 10, 11, 12) Exclusion Criteria The presence of any of the following will preclude patient inclusion: - History or presence of existing interstitial lung disease. - Current clinically significant impairment of cardiac function (greater than Class II according to New York Heart Association [NYHA] classification). - Unstable ischemic heart disease within the last 6 months, including myocardial infarction. - Presence of QTc interval prolongation >480 ms. - Clinically significant corneal or conjunctival eye disease. - Clinically significant skin diseases such as psoriasis, rash or atopic dermatitis. - Clinically significant impairment of GI function or GI disease including total gastrectomy that may alter the absorption of afatinib. - Clinically significant, active peptic ulcer disease. - Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or patients with any untreated serious infections. - Pregnancy and contraception: Female patients of child bearing potential must have a negative serum or urine pregnancy test within 14 days prior to registration/randomisation, and must use an effective method of contraception at least 1 week prior to treatment, during treatment and for at least 28 days after the final dose of study drug. Acceptable methods are: True abstinence (this must be the patients usual and preferred lifestyle, not just for the duration of the study) Oral contraceptive (either combined or progestogen alone) Contraceptive implant, injections or patches Vaginal ring Intrauterine device (IUD, coil or intrauterine system) Condom and cap Diaphragm plus spermicide Tubal Ligation - A female patient of child bearing potential is defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if aged 55 years or younger or 12 months if aged 56 years or older. - Men must use one of the following, reliable forms to contraception for the entire duration of treatment and for 28 days after the final dose of study drug: Condom plus spermicide even if female partner is using another method of contraception (Men should also use a condom to protect male partners, or female partners who are pregnant or breast feeding, from exposure to the study medicine in semen). True abstinence (this must be the patients usual and preferred lifestyle, not just for the duration of the study) - Concurrent severe and/or uncontrolled medical conditions (due to concurrent disease other than cancer) which in the opinion of the investigator could compromise participation in the study. - Known or suspected active drug or alcohol abuse. - Administration of chemotherapy, immunotherapy, radiotherapy or any investigational cancer therapy within 5 half-lives of the prior therapy or 2 weeks of first dose of afatinib, whichever is longer. Continuation of established endocrine therapy is allowed and no washout period is required. Established endocrine therapy (which may include GnRH analogues) is that which has been administered for at least 2 weeks prior to starting afatinib on Day 1 - Known hypersensitivity to afatinib or its excipients. - Toxicities of prior therapies that have not resolved to =CTCAE Grade 1. - Any of the following laboratory test findings: Haemoglobin <90 g/L Absolute neutrophil count <1 x 109 /L Platelet count <100 x 109 /L AST or ALT >2.5 x upper limit of normal range (ULN) Total serum bilirubin >1.5 x ULN Creatinine >1.5 x ULN Creatinine clearance <30mL/min (Cockcroft-Gault) - Patients taking potent P-gp inducers/inhibitors (see section 15.9) - Any other reason which, in the opinion of the Investigator, interferes with the ability of the patient to participate in the study. - Patients unable to comply with the protocol.

Study Design


Intervention

Drug:
Afatinib

Radiation:
2 Gy targeted radiotherapy

4 Gy targeted radiotherapy


Locations

Country Name City State
United Kingdom University Hospitals Birmingham NHS Foundation Trust Birmingham
United Kingdom Cambridge University Hospitals NHS Foundation Trust Cambridge England
United Kingdom The Beatson West of Scotland Cancer Centre Glasgow
United Kingdom Clatterbridge Cancer Centre Liverpool
United Kingdom The Christie NHS Foundation Trust Manchester
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford

Sponsors (5)

Lead Sponsor Collaborator
Cambridge University Hospitals NHS Foundation Trust Boehringer Ingelheim, Cancer Research UK, The Brain Tumour Charity, University of Cambridge

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ratio of afatinib concentration in: [resected brain metastases] / [plasma] - each measured in (ng/mL) on day 12 Day 12 of treatment
Secondary Safety of afatinib alone and combined with targeted low-dose radiotherapy - assessed by number of participants with treatment- related adverse events as assessed by CTCAE v4.0 From consent to Day 41+/-7 days
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A